Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
AssigneeHoechst Aktiengesellschaft
InventorsStefan Mullner, Claudia Dax
Life of this patent
Estimating the term…
Abstract
Compounds of the formula I ##STR1## where one of the radicals R.sup.1 and R.sup.3 is a radical of the formula II --(CH.sub.2).sub.n --A--CH.sub.3 (II) in which A is a covalent bond, --C(O)-- or --C(R.sup.4)(OH)--, are suitable for the production of pharmaceuticals for the modulation of apoptosis. A combination preparation comprising a compound of the formula I and a compound of the formula IV and/or V ##STR2## is suitable for the production of pharmaceuticals for the modulation of apoptosis.
Claims9
A method for inhibiting the dephosphorylation of the protein cofilin comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula I ##STR7## and/or an optionally stereoisomeric form of the compound of the formula and/or a physiologically tolerable salt of the compound of the formula I,
- where
- R.sup.2 is (C.sub.1 -C.sub.4)-alkyl,
- one of the radicals R.sup.1 or R.sup.3 is a radical of the formula II
- --(CH.sub.2).sub.n --R--CH.sub.3
- in which
- R is
- a) a covalent single bond and in which n is the integer zero, 1, 2, 3, 4, 5, 6 or 7,
- b) a radical --CO-- and in which n is the integer 1, 2, 3, 4, 5 or 6, or
- c) a radical --C(R.sup.4)(OH)-- and in which n is the integer 1, 2, 3, 4, 5 or 6 and,
- R.sup.4 is
- a) a hydrogen atom or
- b) (C.sub.1 -C.sub.3)-alkyl, and
- the other radical R.sup.3 or R.sup.1 is
- a) a hydrogen atom,
- b) (C.sub.1 -C.sub.7)-alkyl,
- c) (C.sub.4 -C.sub.8)-cycloalkylalkyl or
- d) alkyl having 2 to 6 carbon atoms, in which the carbon chain is interrupted by an oxygen atom.
A method for inhibiting the dephosphorylation of the protein cofilin comprising administering to a patient in need thereof
- 1) a therapeutically effective amount of a xanthine derivative of the formula I ##STR8## and/or an optionally stereoisomeric form of the compound of the formula I and/or a physiologically tolerable salt of the compound of the formula I,
- wherein
- R.sup.2 is (C.sub.1 -C.sub.4)-alkyl,
- one of the radicals R.sup.1 or R.sup.3 is a radical of the formula II
- --(CH.sub.2).sub.n)--R--CH.sub.3 (II)
- in which R
- a) is a covalent single bond and in which n is the integer zero, 1, 2, 3, 4, 5, 6 or 7,
- b) is a radical --CO-- and in which n is the integer 1, 2, 3, 4, 5 or 6, or
- c) is a radical --C(R.sup.4)(OH)-- and in which n is the integer 1, 2, 3, 4, 5 or 6 and
- R.sup.4 is
- a) a hydrogen atom or
- b) (C.sub.1 -C.sub.3)-alkyl, and
- the other radical R.sup.3 or R.sup.1 is
- a) a hydrogen atom,
- b) (C.sub.1 -C.sub.7)-alkyl,
- c) (C.sub.4 -C.sub.8)-cycloalkylalkyl or
- d) alkyl having 2 to 6 carbon atoms, in which the carbon chain is interrupted by an oxygen atom;
- in conjunctive therapy with
- 2) a therapeutically effective amount of a compound of the formula IV and/or V, ##STR9## and/or an optionally stereoisomeric form of the compound of the formula IV or V and/or a physiologically tolerable salt of the compound of the formula IV or V, wherein
- R.sup.5 is
- a) (C.sub.1 -C.sub.4)-alkyl,
- b) (C.sub.3 -C.sub.5)-cycloalkyl,
- c) (C.sub.2 -C.sub.6)-alkenyl or
- d) (C.sub.2 -C.sub.6)-alkynyl,
- R.sup.6 is
- a) --CF.sub.3,
- b) --O--CF.sub.3,
- c) --S--CF.sub.3,
- d) --OH,
- e) --NO.sub.2,
- f) halogen,
- g) benzyl,
- h) phenyl,
- i) --O-phenyl,
- k) --CN or
- l) --O-phenyl, mono- or polysubstituted by
- 1) (C.sub.1 -C.sub.4)-alkyl,
- 2) halogen,
- 3) --O--CF.sub.3 or
- 4) --O--CH.sub.3,
- R.sup.7 is
- a) (C.sub.1 -C.sub.4)-alkyl,
- b) halogen, or
- c) a hydrogen atom, and
- X is
- a) a --CH group or
- b) a nitrogen atom.
Dependencies are inferred from the claim text.